The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Pre-clinical research on GLP1-RAs suggests potential cognitive preservation through reduced amyloid-beta accumulation, decreased neuroinflammation, enhanced synaptic plasticity, and improved mitochondrial function in neurons. (14, 15).
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
when you look at some of the Alzheimer's biomarkers um which are improving improving significantly um it begs the question should this be part of the playbook for an individual who's at high risk especially given that we now I think really understand how to make sure people don't lose weight and don't lose lean mass and therefore I suspect don't lose bone density and all these other things that matter